Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.
Jonathan D Tward, Lauren Lenz, Alexander Gutin, Wyatt Clegg, Chelsea R Kasten, Robert Finch, Todd Cohen, Jeff Michalski, Amar U Kishan
May 2024 JCO Precis OncolSynopsis of Social media discussions
Many discussions highlight how the CCR score could transform personalized prostate cancer treatment, with phrases like 'tailored therapy' and 'predictive power.' Users show enthusiasm by referencing the potential for better patient outcomes, showing both curiosity and recognition of its significance, while some cite specific data points like the absolute risk reduction to emphasize its practical value.
Agreement
Moderate agreementMajority of discussions recognize the study's importance, with users appreciating its contribution to personalized treatment strategies.
Interest
High level of interestDiscussions show high interest, with many expressing curiosity about how the CCR score can influence clinical decisions.
Engagement
Moderate level of engagementPosts often delve into the methodology and implications of the study, indicating a moderate level of in-depth engagement.
Impact
High level of impactThe shared opinions suggest the study could significantly influence prostate cancer treatment approaches, highlighting its potential clinical impact.
Social Mentions
YouTube
1 Videos
1 Posts
News
20 Articles
Metrics
Video Views
35
Extended Reach
1,282
Social Features
22
Timeline: Posts about article
Top Social Media Posts
Adela
Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer | JCO Precision Oncology https://t.co/R4pGRtQuuj
view full post
Posts referencing the article
Using CCR Score to Personalize Prostate Cancer Therapy Benefits
This video discusses a study that uses a personalized clinical cell-cycle risk score to predict the benefit of adding androgen deprivation therapy to radiation therapy in newly diagnosed prostate cancer patients. The CCR score helps tailor treatment decisions for improved outcomes.
August 21, 2024
35 views
-
Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer | JCO Precision Oncology https://t.co/R4pGRtQuuj
view full postMay 22, 2024
Abstract Synopsis
- This text discusses a study that uses a mathematical model based on a personalized clinical cellcycle risk (CCR) score to predict how much benefit patients with newly diagnosed prostate cancer might get from adding androgen deprivation therapy (ADT) to radiation therapy (RT).
- The model shows that patients with higher CCR scores are more likely to benefit significantly from ADT, with an absolute risk reduction of up to 17.1% and a number needed to treat as low as 6, meaning fewer patients need treatment for one to benefit.
- Overall, the CCR score helps tailor treatment decisions by accurately estimating 10-year metastasis risk, allowing physicians and patients to make more personalized and informed choices about intensifying therapy.
Adela
@adelapoite (Twitter)